United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
PURPOSE: To determine the safety and efficacy of arsenic trioxide (ATO) in patients with relapsed acute promyelocytic leukemia (APL). PATIENTS AND METHODS: Forty patients experiencing first (n = 21) or ≥ second (n = 19) relapse were treated with daily infusions of ATO to a maximum of 60 doses or until all leukemic cells in bone marrow were eliminated. Patients who achieved a complete remission (CR) were offered one consolidation course of ATO that began 3 to 4 weeks later. Patients who remained in CR were eligible to receive further cycles of ATO therapy on a maintenance study. RESULTS: Thirty-four patients (85%) achieved a CR. Thirty-one patients (91%) with CRs had posttreatment cytogenetic tests negative for t(15;17). Eighty-six percent of the patients who were assessable by reverse transcriptase polymerase chain reaction converted from positive to negative for the promyelocytic leukemia/retinoic acid receptor-alpha transcript by the completion of their consolidation therapy. Thirty-two patients received consolidation therapy, and 18 received additional ATO as maintenance. Eleven patients underwent allogeneic (n = 8) or autologous (n = 3) transplant after ATO treatment. The 18-month overall and relapse-free survival (RFS) estimates were 66% and 56%, respectively. Twenty patients (50%) had leukocytosis (> 10,000 WBC/μL) during induction therapy. Ten patients developed signs or symptoms suggestive of the APL syndrome and were effectively treated with dexamethasone. Electrocardiographic QT prolongation was common (63%). One patient had an absolute QT interval of > 500 msec and had an asymptomatic 7-beat run of torsades de pointe. Two patients died during induction, neither from drug-related causes. CONCLUSION: This study establishes ATO as a highly effective therapy for patients with relapsed APL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Shen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Kakizuka, A., Miller, W. H., Umesono, K., Warrell, R. P., Frankel, S. R., Murty, V. V. V. S., Dmitrovsky, E., & Evans, R. M. (1991) · Cell · doi:10.1016/0092-8674(91)90112-c · Cited by 1,427
Self-citationde Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355
Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
Soignet, S. L., Maslak, P., Wang, Z.-G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391901 · Cited by 1,213
Self-citationAll-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C. D., Rowe, J. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371501 · Cited by 1,073
Self-citationWarrell, R. P., de The, H., Wang, Z.-Y., & Degos, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290307 · Cited by 776
Self-citationHe, L.-Z., Figueiredo-Pontes, L. L., Rego, E. M., & Pandolfi, P. P. (2015) · Encyclopedia of Cancer · doi:10.1007/978-3-662-46875-3_63 · Cited by 766
Cited by
Heavy Metal Toxicity and the Environment
Tchounwou, P. B., Yedjou, C. G., Patlolla, A. K., & Sutton, D. J. (2012) · Experientia Supplementum · doi:10.1007/978-3-7643-8340-4_6 · Cited by 7,192
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Sanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationCardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Acute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
Self-citationAnticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Burnett, A. K., Russell, N. H., Hills, R. K., Bowen, D., Kell, J., Knapper, S., Morgan, Y. G., Lok, J., Grech, A., Jones, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00193-x · Cited by 534
From traditional Chinese medicine to rational cancer therapy
Efferth, T., Li, P. C. H., Konkimalla, V. S. B., & Kaina, B. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.07.001 · Cited by 528
Lazo, G., Kantarjian, H., Estey, E., Thomas, D., O'Brien, S., & Cortes, J. (2003) · Cancer · doi:10.1002/cncr.11314 · Cited by 494
Self-citationTallman, M. S. (2002) · Blood · doi:10.1182/blood-2002-02-0632 · Cited by 482
Self-citationCancer drugs and the heart: importance and management
Suter, T. M., & Ewer, M. S. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs181 · Cited by 472
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Acute promyelocytic leukemia: evolving therapeutic strategies
Tallman, M. S., Nabhan, C., Feusner, J. H., & Rowe, J. M. (2002) · Blood · doi:10.1182/blood.v99.3.759 · Cited by 398
Self-citationDilda, P. J., & Hogg, P. J. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.05.001 · Cited by 389
Estey, E., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Verstovsek, S., Jones, D., & Kantarjian, H. (2006) · Blood · doi:10.1182/blood-2005-10-4006 · Cited by 384
Self-citationPowell, B. L., Moser, B., Stock, W., Gallagher, R. E., Willman, C. L., Stone, R. M., Rowe, J. M., Coutre, S., Feusner, J. H., Gregory, J., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269621 · Cited by 382
Self-citationRavandi, F., Estey, E., Jones, D., Faderl, S., O'Brien, S., Fiorentino, J., Pierce, S., Blamble, D., Estrov, Z., Wierda, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6130 · Cited by 376
Self-citationCardiotoxicity of Cancer Therapy
Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., & Perry, M. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.789 · Cited by 372
Differentiation therapy of leukemia: 3 decades of development.
Nowak, D., Stewart, D., & Koeffler, H. P. (2009) · Blood · doi:10.1182/blood-2009-01-198911 · Cited by 348
Grimwade, D., Jovanovic, J. V., Hills, R. K., Nugent, E. A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1533 · Cited by 356
Mathews, V., George, B., Lakshmi, K. M., Viswabandya, A., Bajel, A., Balasubramanian, P., Shaji, R. V., Srivastava, V. M., Srivastava, A., & Chandy, M. (2006) · Blood · doi:10.1182/blood-2005-08-3532 · Cited by 343
Iland, H. J., Bradstock, K., Supple, S. G., Catalano, A., Collins, M., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Hugman, A., et al. (2012) · Blood · doi:10.1182/blood-2012-02-410746 · Cited by 329
Heavy Metal Contamination of Natural Foods Is a Serious Health Issue: A Review
Munir, N., Jahangeer, M., Bouyahya, A., El Omari, N., Ghchime, R., Balahbib, A., Aboulaghras, S., Mahmood, Z., Akram, M., Ali Shah, S. M., et al. (2021) · Sustainability · doi:10.3390/su14010161 · Cited by 322
Cardiovascular Complications of Cancer Therapy
Chang, H.-M., Okwuosa, T. M., Scarabelli, T., Moudgil, R., & Yeh, E. T. H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1095 · Cited by 290
Mechanisms of Arsenic-Induced Prolongation of Cardiac Repolarization
Ficker, E., Kuryshev, Y. A., Dennis, A. T., Obejero-Paz, C., Wang, L., Hawryluk, P., Wible, B. A., & Brown, A. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.1.33 · Cited by 286
Abaza, Y., Kantarjian, H., Garcia-Manero, G., Estey, E., Borthakur, G., Jabbour, E., Faderl, S., O’Brien, S., Wierda, W., Pierce, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-736686 · Cited by 286
Self-citationHow I treat acute promyelocytic leukemia
Tallman, M. S., & Altman, J. K. (2009) · Blood · doi:10.1182/blood-2009-07-216457 · Cited by 284
Self-citationArsenic trioxide — An old drug rediscovered
Emadi, A., & Gore, S. D. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.04.001 · Cited by 279
Mathews, V., George, B., Chendamarai, E., Lakshmi, K. M., Desire, S., Balasubramanian, P., Viswabandya, A., Thirugnanam, R., Abraham, A., Shaji, R. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5031 · Cited by 252
Citarella, A., Catanzaro, G., Besharat, Z. M., Trocchianesi, S., Barbagallo, F., Gosti, G., Leonetti, M., Di Fiore, A., Coppola, L., Autilio, T. M., et al. (2023) · Cancers · doi:10.3390/cancers15051471 · Cited by 27
“Arsenic Trioxide (ATO) is an organic compound approved for the therapy of adult patients with acute promyelocytic leukemia [25] and was shown to successfully inhibit both HH-GLI and NOTCH pathways [26].”
Background
Metadata
- Authors
- Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., Sievers, E. L., Coutré, S., Dahlberg, S., Ellison, R., & Warrell, R. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-09-15
- Volume
- 19
- Issue
- 18
- Pages
- 3852-3860
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1931891535
- Cited by
- 826
- References
- 23
- FWCI
- 17.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.